K. Sankhala

发表

Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin

A. Tolcher, K. Papadopoulos, A. Patnaik, 2011, Clinical Cancer Research.

A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS).

A. B. Hassan, J. Blay, A. Italiano, 2017 .

Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow

F. Giles, D. Mahalingam, K. Sankhala, 2009, Leukemia & lymphoma.

Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives

K. Sankhala, S. Chawla, E. Gordon, 2016, Advances in Therapy.

Aldoxorubicin for the treatment of advanced soft tissue sarcoma

K. Sankhala, S. Chawla, N. Chawla, 2015 .

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma

D. Quon, K. Sankhala, S. Chawla, 2015, Cancer.

A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin.

M. Beeram, A. Mita, K. Sankhala, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules

C. Takimoto, S. Kopetz, A. Mita, 2019, Investigational New Drugs.

A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors

A. Gianella-Borradori, M. Mita, A. Mita, 2014, Targeted Oncology.

First-in-human phase 1 dose-escalation study of AV-203, a monoclonal antibody against ERBB3, in patients with metastatic or advanced solid tumors.

T. Owonikoko, S. Ramalingam, P. Komarnitsky, 2014 .

Targeting sarcomas: novel biological agents and future perspectives.

F. Giles, D. Mahalingam, M. Mita, 2009, Current drug targets.

A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Robin L. Jones, P. Hwu, Hailing Lu, 2020, Oncoimmunology.

Deforolimus (AP23573) a novel mTOR inhibitor in clinical development.

F. Giles, M. Mita, A. Mita, 2008, Expert opinion on investigational drugs.

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents

F. Giles, D. Mahalingam, M. Mita, 2009, Targeted Oncology.

Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors

N. Senzer, J. Nemunaitis, D. Mahalingam, 2014, Cancer Chemotherapy and Pharmacology.

Clinical experience with combination chemo-/immunotherapy using trabectedin and nivolumab for advanced soft tissue sarcoma.

K. Sankhala, S. Chawla, E. Gordon, 2018 .

Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas.

J. Blay, G. Demetri, A. Tolcher, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early response evaluation of therapy with AP23573 (an mTOR inhibitor) in sarcoma using [18F]2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) scan

G. Demetri, A. Iagaru, C. Bedrosian, 2005 .

Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia

M. Minden, G. Curt, H. Kantarjian, 2012, Investigational New Drugs.

The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas

M. Mita, A. Mita, K. Sankhala, 2011, Targeted Oncology.

Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.

C. Shapiro, M. Mita, A. Mita, 2014, Clinical breast cancer.

A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results.

L. Chirieac, G. Shapiro, S. Rodig, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

D. Schiff, W. Wick, G. Tabatabai, 2021, Clinical Cancer Research.

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.

J. Blay, G. Demetri, T. Clackson, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting the mTOR pathway using deforolimus in cancer therapy.

Francis J Giles, F. Giles, D. Mahalingam, 2009, Future oncology.

Potential of mTOR inhibitors as therapeutic agents in hematological malignancies

F. Giles, K. Sankhala, 2009, Expert review of hematology.

Deforolimus (AP23573) a novel mTOR inhibitor in clinical development

F. Giles, M. Mita, A. Mita, 2008, Expert opinion on investigational drugs.

Future options for imatinib mesilate-resistant tumors

K. Papadopoulos, K. Sankhala, 2007, Expert opinion on investigational drugs.

Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma

A. Tolcher, J. Michalek, M. Beeram, 2010, Cancer Chemotherapy and Pharmacology.

Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies

K. Sankhala, 2017, Expert opinion on investigational drugs.

Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant

F. Giles, S. Soefje, K. Sankhala, 2009, Expert opinion on drug metabolism & toxicology.

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

A. Tolcher, E. Rasmussen, C. Takimoto, 2010, Clinical Cancer Research.

Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors

A. Brenner, R. Kurzrock, S. Moulder, 2011, Molecular Cancer Therapeutics.

Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?

S. Ferrari, P. Picci, K. Sankhala, 2017, European journal of cancer.

First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors

Jennifer L Moseley, A. Tolcher, S. Kopetz, 2008 .

First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.

K. Ganjoo, A. Fedenko, K. Sankhala, 2015, JAMA oncology.

Recurrent angiokeratoma scroti: a case report

K. Sankhala, S. Tomar, B. Thakur, 2013 .

Combined Central Retinal Artery and Vein Occlusion with Ischemic Optic Neuropathy After COVID-19 Vaccination

K. Sankhala, R. Gallemore, S. Bose, 2022, International medical case reports journal.

A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).

R. Maki, R. Riedel, K. Sankhala, 2016 .

Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results.

R. Advani, J. Vose, S. Horwitz, 2009 .

A phase II study of intravenous (IV) wild-type reovirus (Reolysin) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung.

S. Goel, M. Mita, K. Sankhala, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Review: desmoplastic small round cell tumor: current treatment approach and role of targeted therapy.

K. Sankhala, S. Chawla, 2009, Clinical advances in hematology & oncology : H&O.

A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas

G. Demetri, C. Bedrosian, K. Sankhala, 2005 .

Heat shock proteins: a potential anticancer target.

C. Takimoto, M. Mita, A. Mita, 2011, Current drug targets.

Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab (B) in combination with sorafenib (S) in patients (pts) with advanced malignant melanoma.

A. Tolcher, J. Michalek, M. Beeram, 2010 .

A phase I, first-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of IMGN853 in patients (Pts) with epithelial ovarian cancer (EOC) and other FOLR1-positive solid tumors.

M. Birrer, P. LoRusso, K. Sankhala, 2013 .

A phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors

A. Tolcher, A. Patnaik, M. Mita, 2007 .

Targeting the mTOR pathway using deforolimus in cancer therapy.

F. Giles, D. Mahalingam, M. Mita, 2009, Future Oncology.